Section Review: Cardiovascular & Renal: Glycoprotein IIb/IIIa antagonists
- 1 November 1996
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 6 (11) , 1175-1194
- https://doi.org/10.1517/13543776.6.11.1175
Abstract
Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists have been shown to be effective in reducing the rate of ischaemic complications due to pathophysiological conditions such as atherosclerosis or coronary intervention. This review will cover all patenting activity in this now mature field of research up to and including August 1996, and will focus on the more significant patents and patent applications.Keywords
This publication has 32 references indexed in Scilit:
- Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffoldBioorganic & Medicinal Chemistry Letters, 1996
- Animal Pharmacokinetics and Interspecies Scaling from Animals to Man of Lamifiban, a New Platelet Aggregation InhibitorJournal of Pharmacy and Pharmacology, 1996
- Optimal Antagonism of GPIIb/IIIa Favors Platelet Adhesion by Inhibiting Thrombus GrowthArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Review Cardiovascular & Renal; Recent Developments in Glycoprotein llb/llla AntagonistsExpert Opinion on Therapeutic Patents, 1995
- Section Review: Cardiovascular & Renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitorsExpert Opinion on Investigational Drugs, 1995
- Synthesis and antiplatelet activity of DMP 757 analogsBioorganic & Medicinal Chemistry Letters, 1995
- Antithrombotic agents: From RGD to peptide mimeticsBioorganic & Medicinal Chemistry, 1995
- Abciximab (c7E3 Fab)Drugs, 1994
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988